Skip to main content
. 2021 Jun 29;11(7):615. doi: 10.3390/jpm11070615

Figure 1.

Figure 1

SSRI metabolism and the effects of cannabidiol (CBD) and tetrahydrocannabinol (THC) on CYP2C19 and CYP2D6 activity. Both CBD and THC inhibit CYP2C19, decreasing the metabolism of CYP2C19 substrates, including sertraline and es/citalopram, delaying production of active metabolites. THC and CBD have a reduced effect on CYP2D6, indicated by the thickness of the lines showing inhibition.